Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Announces Incoming CEO and President

Published: Tuesday, April 15, 2014
Last Updated: Tuesday, April 15, 2014
Bookmark and Share
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.

Dr. Batra will assume leadership effective May 15, 2014 and be based at the company’s U.S. headquarters in Massachusetts. 

“As a global leader in the Life Sciences industry, I am very humbled and excited to be a part of Merck Millipore team and look forward to serving our customers globally,” Dr. Batra said. “As a former researcher who personally utilized the strong differentiated products that Merck Millipore offers, I have watched this organization develop over the past several years, and look forward to further building upon that success to bring continued value to our customers and other stakeholders.”

Dr. Batra comes to Merck Millipore from the Consumer Health division of Merck KGaA, where he successfully grew the business in established and emerging markets. He previously worked at Novartis Vaccines & Diagnostics, where he was Head of Global Public Health and Market Access. Prior to that, he served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.

Dr. Batra started his career as a research engineer at Merck & Co. In 2001, he joined McKinsey where he worked across the healthcare, consumer and nonprofit sectors as a senior engagement manager. In 2004, he was appointed global Brand Director for the Wound Care Franchise at Johnson & Johnson, before joining Novartis in 2006.

Dr. Batra is a member of the WSMI (World Self Medication Industry) and the Chair of the Food Supplements Committee of the AESGP (Association of the European Self-Medication Industry).

He holds a Ph.D. in chemical engineering from Princeton University and a bachelor’s degree in chemical engineering from the University of Delaware. 

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos